logo.jpg
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
July 11, 2024 08:00 ET | Samsung Bioepis
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
Coherus_Logo_RGB_150.png
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
June 27, 2024 08:26 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend...
22157.jpg
US HUMIRA Market Projected for Extensive Growth by 2032 in Noninfectious Autoimmune Uveitis Sector
February 28, 2024 11:05 ET | Research and Markets
Dublin, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The "US HUMIRA Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering. An insightful analysis...
Global Dupuytren’s Disease Market
Global Dupuytren's Disease Research Report 2023: A $5.87 Billion Market by 2030 - Injectable Collagenase Therapies Revolutionize Contracture Management
December 11, 2023 09:18 ET | Research and Markets
Dublin, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The "Dupuytren's Disease Market Size, Share & Trends Analysis Report By Type (Diagnosis, Treatment), By Disease Type (Type I, Type II), By End-use...
Amgen’s Amjevita Rem
Amgen’s Amjevita Remains the Frontrunner in the US Adalimumab Biosimilars Market, Despite Increased Competition, According to Spherix Global Insights.
September 14, 2023 11:37 ET | Spherix Global Insights
Exton, Pennsylvania, Sept. 14, 2023 (GLOBE NEWSWIRE) -- This summer ushered in the highly anticipated introduction of a multitude of additional adalimumab biosimilars to the dynamic US immunology...
Rani-Logo.jpg
Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update
August 11, 2023 16:05 ET | Rani Therapeutics, LLC
- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three...
Rani-Logo.jpg
Rani Therapeutics to Participate in August Investor Conferences
August 04, 2023 16:05 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
YUSIMRY™ (adalimumab-aqvh) product image
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
July 13, 2023 08:30 ET | Coherus BioSciences, Inc.
First formal distribution agreement for YUSIMRY™, a biosimilar of Humira®, at $995 per carton (two 40 mg/0.8 mL autoinjectors) representing a discount of more than 85% compared to HumiraInnovative...
YUSIMRY™ (adalimumab-aqvh) product image
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
July 03, 2023 08:30 ET | Coherus BioSciences, Inc.
–$995 per carton (two 40 mg/0.8 mL autoinjectors) represents a discount of more than 85% compared to Humira® – – YUSIMRY™ meets high unmet need by providing patients, employers, physicians and...
Coherus Logo - R@2x.png
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
June 01, 2023 08:33 ET | Coherus BioSciences, Inc.
–  YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company  – –  YUSIMRY will be available on costplusdrugs.com for $569.27 plus dispensing and...